BEOVU

novartis pharmaceuticals canada inc🇨🇦 Health Canada

Approval Id: ec2508ac215c6bc1
Drug Approval Canada Name: BEOVU
Product Name: BEOVU
Status: Marketed
Status Date: 2020-05-15
Original Market Date: 2020-05-15
Din: 02496976
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravitreal
Schedule: Prescription
Ahfs: 52:92.00
Atc Original: S01LA06 BROLUCIZUMAB
Atc Name: s 01 la 06
Aig Number: 0162094001
Company Name: novartis pharmaceuticals canada inc
Company Address: 100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1

BROLUCIZUMAB

6 MG / 0.05 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

ec2508ac215c6bc1

Type

Standard